Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Focus on renal morphology, chronic kidney disease, and urinary system malignancies in acromegaly: report on data collected over a 40-year period.

Pituitary·2026
Same author

Cancer risk in a large acromegaly cohort: a standardized incidence ratio analysis.

Pituitary·2026
Same author

Evaluation of Dry Eye Parameters in Patients with Papillary Thyroid Carcinoma.

Journal of clinical medicine·2026
Same author

Evaluation of large language models for carbohydrate counting in type 1 diabetes mellitus: a comparative study with patient estimations.

Diabetes research and clinical practice·2026
Same author

Diagnostic Utility of ACTH, Cortisol, DHEAS, and Their Derived Ratios in Cushing's Syndrome Subtypes.

Journal of clinical medicine·2026
Same author

Heterogeneity in endocrine monitoring and timing of endocrinology involvement during immune checkpoint inhibitor therapy: A Real-World Single-Center study.

Endocrine·2026

Related Experiment Video

Updated: Jun 1, 2026

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

Systemic mastocytosis.

Didem Ozdemir1, Selcuk Dagdelen, Tomris Erbas

  • 1Department of Internal Medicine, Hacettepe University Medical School, Ankara, Turkey. sendidem2002@yahoo.com

The American Journal of the Medical Sciences
|June 2, 2011
PubMed
Summary
This summary is machine-generated.

Systemic mastocytosis (SM) is a clonal disorder of mast cells. Diagnosis involves identifying mast cell aggregates, with WHO classifying SM into six variants impacting prognosis and treatment.

More Related Videos

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

Related Experiment Videos

Last Updated: Jun 1, 2026

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

Area of Science:

  • Hematology
  • Oncology

Background:

  • Systemic mastocytosis (SM) is a clonal hematopoietic disorder involving abnormal mast cell proliferation.
  • Clinical presentation varies from mild to aggressive, life-threatening disease.
  • Differential diagnosis includes conditions like pheochromocytoma and carcinoid syndrome.

Purpose of the Study:

  • To provide an overview of Systemic Mastocytosis.
  • To discuss diagnostic criteria and WHO classification.
  • To outline prognostic factors and treatment strategies.

Main Methods:

  • Review of existing literature and diagnostic criteria.
  • Classification based on World Health Organization (WHO) guidelines.
  • Analysis of clinical presentation, diagnosis, and treatment outcomes.

Main Results:

  • SM is characterized by mast cell aggregates in bone marrow or other tissues.
  • WHO classification includes indolent SM, aggressive SM, and rarer forms.
  • Prognosis varies significantly, with indolent SM having a favorable outlook.

Conclusions:

  • Systemic Mastocytosis diagnosis requires identifying mast cell aggregates.
  • WHO classification aids in determining prognosis and guiding treatment.
  • Aggressive SM necessitates cytoreductive therapy, while indolent forms may only require symptomatic management.